Aldeyra Therapeutics, Inc.Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment Advice
This page was updated : N/A. Premium customers can update this page on demand.
Based on these articles
Yahoo - Business Overview
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, ...
Risk Rating (Yahoo)
ESG Score (Yahoo)
Market Cap (USD)
Flags & Key Risks
2 months ago @Seeking Alpha
Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call Transcript
|#ALDX #sa-transcripts #aldx #transcripts #bullets #summary|
6 days ago @DEF 14A
DEF 14A - Proxy Statements
|#ALDX #regulatory filing #proxy #statements #ALDX|
|No lawsuits found for|